Results 171 to 180 of about 54,917 (299)

Changes in Metabolic and Blood Pressure Outcomes With Semaglutide Across Chronic Kidney Disease Stages: A Post Hoc Analysis of the FLOW Trial

Diabetes, Obesity and Metabolism, EarlyView.
ABSTRACT Aims To assess changes in glycated haemoglobin (HbA1c), body weight, and systolic/diastolic blood pressure (SBP/DBP) by chronic kidney disease (CKD) and albuminuria categories in a post hoc analysis of FLOW, an international, double‐blind, randomized, phase 3b clinical trial of adults with CKD and Type 2 diabetes (T2D).
Allon N. Friedman, Jan Basile, Robert Busch, David M. Charytan, Kenneth W. Mahaffey, Sherif Mehanna, Søren Rasmussen, Peter Rossing, Caroline Swift, Katherine R. Tuttle, Richard Pratley   +10 more
wiley   +1 more source

Concordance Between Trial Efficacy and Real-World Effectiveness of Sodium-Glucose Cotransporter 2 Inhibitors in Heart Failure With Reduced Ejection Fraction: A Systematic Review and Meta-Analysis. [PDF]

Cureus
Hassanien A, Elhenedy M, Elgohari M.
europepmc   +1 more source

Diabetes and menopause: A critical yet neglected intersection

Diabetic Medicine, EarlyView.
Isabell Haage, David Studer, Petra Stute, Lia Bally   +3 more
wiley   +1 more source

The Ahlqvist Subphenotypes of Type 2 Diabetes: A Narrative Review of Scientific Evidence and Its Potential Contribution to Precision Diabetes

Diabetes, Obesity and Metabolism, EarlyView.
ABSTRACT Background Among several approaches, k‐means clustering has established as a widely used method to classify people with type 2 diabetes (T2D) into distinct subphenotypes, and the Ahlqvist T2D subphenotypes of Severe Insulin Deficient Diabetes (SIDD), Mild Age‐Related Diabetes (MARD), Mild Obesity Diabetes (MOD) and Severe Insulin Resistant ...
Wolfgang Landgraf, David R. Owens, Brian M. Frier, Geremia B. Bolli   +3 more
wiley   +1 more source

SGLT2 Inhibition

Journal of the American College of Cardiology, 2019
openaire   +1 more source

Acute Effects of Acarbose and Canagliflozin, Alone and in Combination, on Postprandial GLP‐1 and Glycaemic Responses in Post‐Bariatric Hypoglycaemia: A Randomised Crossover Study

Diabetes, Obesity and Metabolism, EarlyView.
ABSTRACT Aim To evaluate the acute effects of acarbose and canagliflozin, alone and in combination, on postprandial total GLP‐1 and glycaemic responses during a mixed meal test in adults with post‐bariatric hypoglycaemia (PBH). Materials and Methods This single‐centre, randomised, four‐period crossover physiological study included 12 adults with PBH ...
Wei Yang, Anna Kowalka, Lara Jimenez‐Pacheco, Veronica Greener, Kleopatra Alexiadou, Ahmed Ahmed, Julia Kenkre, Chioma Izzi‐Engbeaya, Saira Hameed, Harvinder Chahal, Bernard Khoo, Tricia M.‐M. Tan   +11 more
wiley   +1 more source

Neuropsychiatric Outcomes Associated With GLP‐1 Receptor Agonist Use in Medicare Beneficiaries With Type 2 Diabetes: Variation by Treatment Pattern and Obesity Status

Diabetes, Obesity and Metabolism, EarlyView.
ABSTRACT Aims Glucagon‐like peptide‐1 (GLP‐1) receptors are expressed in brain regions governing mood, reward and stress, yet the neuropsychiatric effects of GLP‐1 receptor agonist (GLP‐1 RA) therapy remain poorly characterized. We estimated associations between GLP‐1 RA use and neuropsychiatric disorders and variation by obesity status and treatment ...
Seo Hyon Baik, Fitsum Baye, Haotian Xian, Kin Wah Fung, Clement J. McDonald   +4 more
wiley   +1 more source

Renoprotective effects and safety of sodium-glucose cotransporter 2 inhibitors in diabetic chronic kidney disease: A systematic review and meta-analysis. [PDF]

Medicine (Baltimore)
Shi X, Fu K, Hu M, Li R, Li H, Xu S.
europepmc   +1 more source

Semaglutide, Tirzepatide and Clinically Recorded Alcohol‐Related Outcomes in Type 2 Diabetes: A Target Trial Emulation

Diabetes, Obesity and Metabolism, EarlyView.
ABSTRACT Aims To compare the risk of incident alcohol use disorder (AUD) among adults with Type 2 diabetes (T2D) initiating semaglutide, tirzepatide or sodium‐glucose cotransporter‐2 inhibitors (SGLT2i). Materials and Methods We conducted a target trial emulation using de‐identified electronic health record data from the TriNetX research network (June ...
Huilin Tang, Bingyu Zhang, Ying Lu, Yiwen Lu, Haoyuan Wang, Christal N. Davis, Henry R. Kranzler, Yong Chen   +7 more
wiley   +1 more source

SGLT2 inhibitors and exercise in diabetic kidney disease: mechanistic rationale, emerging clinical evidence, and future perspectives. [PDF]

Front Med (Lausanne)
Li H, Ai M, He X, Liu C, Ju X.
europepmc   +1 more source